<n-docbody><doc bill="Y"><content.metadata.block><cmd.identifiers><cmd.cites><cmd.second.line.cite><bop/><bos/>Multidistrict Lit Man § 6:15<eos/><eop/></cmd.second.line.cite></cmd.cites></cmd.identifiers></content.metadata.block><prop.block><prop.head toc-guid=""><bop/><bos/><headtext>Multidistrict Litigation Manual</headtext><eos/><eop/></prop.head><content.metadata.block><cmd.dates><cmd.currency.default iso.d="20190501"><bop/><bos/>May 2019 Update<eos/><eop/></cmd.currency.default></cmd.dates></content.metadata.block><author.line><bop/><bos/><author>David F. Herr[<footnote.reference refid="If5500fc16b3e11e99b03e53d6dd36aa2">a0</footnote.reference>]</author><eos/><eop/></author.line><prop.head toc-guid="I97b7f560933b11da99e2b07024dacc26"><bop/><bos/><label.name>Part</label.name><label.designator>I.</label.designator><headtext>Handling Cases Before the Judicial Panel on Multidistrict Litigation</headtext><eos/><eop/></prop.head><prop.head toc-guid="I1c3ad730933c11da99e2b07024dacc26"><bop/><bos/><label.name>Chapter</label.name><label.designator>6.</label.designator><headtext>Selection of a Transferee District</headtext><eos/><eop/></prop.head></prop.block><message.block><include.copyright n-include_collection="w_wlnv_msg" n-include_guid="I1DA35ED81DD211B281BAD200220BDFCA">Copyright (c) 2017 Thomson/RIA All rights reserved.</include.copyright></message.block><section><section.front><doc.title toc-guid="I94f3c38de1e311da9c26e67ca3b71335"><head parent="doc.title"><bop/><bos/><label.name>§ </label.name><label.designator>6:15.</label.designator><headtext>Factors articulated by the Panel in selecting transferee district—Overall experience of judge</headtext><eos/><eop/></head></doc.title></section.front><section.body><para><bop/><bos/><paratext>The Panel has repeatedly indicated its preference for transferring multidistrict cases to courts with experience handling complex cases.[<eos/><bos/><footnote.reference refid="If55036d06b3e11e99b03e53d6dd36aa2">1</footnote.reference>] This factor is rarely the primary basis for selecting a transferee district, but it may be an important factor in the selection decision. <eos/><bos/>This factor is more important, however, on the question of selecting a specific judge rather than a judicial district.[<eos/><bos/><footnote.reference refid="If5505de06b3e11e99b03e53d6dd36aa2">2</footnote.reference>] Because the availability of a judge experienced in the management of complex litigation is important to the Panel, it may affect the transfer decision itself[<footnote.reference refid="If55084f06b3e11e99b03e53d6dd36aa2">3</footnote.reference>] or the selection of a district.[<eos/><bos/><footnote.reference refid="If55084f16b3e11e99b03e53d6dd36aa2">4</footnote.reference>] This factor is discussed in greater detail in Chapter 7.</paratext><eos/><eop/></para><para><bop/><bos/><paratext>This factor is a difficult one for the parties to advance. <eos/><bos/>By implication, it requires the suggestion that the judge or judges in alternative transferee districts are not as capable of handling the litigation. <eos/><bos/>The Panel has rejected arguments concerning this factor and found them “wholly without merit.”[<eos/><bos/><footnote.reference refid="If55084f26b3e11e99b03e53d6dd36aa2">5</footnote.reference>] Experience handling similar MDL dockets can be particularly persuasive, and may be something more readily advanced by a party.<eos/></paratext><eop/></para></section.body></section><author.footnotes><footnote ID="If5500fc16b3e11e99b03e53d6dd36aa2"><label.designator>a0</label.designator><footnote.body><para><bop/><bos/><paratext>Maslon Edelman Borman &amp; Brand, LLP, Minneapolis, Minnesota.<eos/></paratext><eop/></para></footnote.body></footnote></author.footnotes><footnote.block><footnote ID="If55036d06b3e11e99b03e53d6dd36aa2"><label.designator>1</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.</ital>, <cite.query w-src-number="0304914076" w-serial-number="2027084586" w-seq-number="00001" w-ref-type="RP" w-pub-number="0004637" ID="I6c7916116b3e11e99779f698461214a6">In re Bayer Healthcare LLC and Merial Limited Flea Control Products Marketing and Sales Practices Litigation, 844 F. Supp. 2d 1369 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914076" w-serial-number="2026993399" w-seq-number="00002" w-ref-type="RP" w-pub-number="0004637" ID="I6c7916136b3e11e99779f698461214a6">In re National Football League Players&apos; Concussion Injury Litigation, 842 F. Supp. 2d 1378 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914076" w-serial-number="2026698630" w-seq-number="00003" w-ref-type="RP" w-pub-number="0004637" ID="I6c7916156b3e11e99779f698461214a6">In re A-Power Energy Generation Systems, Ltd. Securities Litigation, 829 F. Supp. 2d 1382 (J.P.M.L. 2011)</cite.query>; <cite.query w-src-number="0304914076" w-serial-number="2026387418" w-seq-number="00004" w-ref-type="RP" w-pub-number="0004637" ID="I6c7916176b3e11e99779f698461214a6">In re Imprelis Herbicide Marketing, Sales Practices and Products Liability Litigation, 825 F. Supp. 2d 1357 (J.P.M.L. 2011)</cite.query>; <cite.query w-src-number="0304914076" w-serial-number="2026340126" w-seq-number="00005" w-ref-type="RP" w-pub-number="0004637" ID="I6c7916196b3e11e99779f698461214a6">In re Wesson Oil Marketing and Sales Practices Litigation, 818 F. Supp. 2d 1383 (J.P.M.L. 2011)</cite.query>; <cite.query w-src-number="0304914076" w-serial-number="2026300732" w-seq-number="00006" w-ref-type="RP" w-pub-number="0004637" ID="I6c79161b6b3e11e99779f698461214a6">In re Citimortgage, Inc., Home Affordable Modification Program (HAMP) Contract Litigation, 816 F. Supp. 2d 1375 (J.P.M.L. 2011)</cite.query>; <cite.query w-src-number="0304914076" w-serial-number="2025913455" w-seq-number="00007" w-ref-type="RP" w-pub-number="0004637" ID="I6c79161d6b3e11e99779f698461214a6">In re Dial Complete Marketing Sales Practices Litigation, 804 F. Supp. 2d 1380 (J.P.M.L. 2011)</cite.query>; <cite.query w-src-number="0304914076" w-serial-number="2025911124" w-seq-number="00008" w-ref-type="RP" w-pub-number="0004637" ID="I6c79161f6b3e11e99779f698461214a6">In re Bank of America Credit Protection Marketing and Sales Practices Litigation, 804 F. Supp. 2d 1372 (J.P.M.L. 2011)</cite.query>; <cite.query w-src-number="0304914076" w-serial-number="2025869229" w-seq-number="00009" w-ref-type="RP" w-pub-number="0004637" ID="I6c7916216b3e11e99779f698461214a6">In re Zimmer Nexgen Knee Implant Products Liability Litigation, 802 F. Supp. 2d 1374 (J.P.M.L. 2011)</cite.query>; <cite.query w-src-number="0304914076" w-serial-number="2025869143" w-seq-number="00010" w-ref-type="RP" w-pub-number="0004637" ID="I6c7916236b3e11e99779f698461214a6">In re Google Android Consumer Privacy Litigation, 802 F. Supp. 2d 1372 (J.P.M.L. 2011)</cite.query>; <cite.query w-src-number="0304914076" w-serial-number="2025867430" w-seq-number="00011" w-ref-type="RP" w-pub-number="0004637" ID="I6c7916256b3e11e99779f698461214a6">In re Certainteed Fiber Cement Siding Litigation, 802 F. Supp. 2d 1369 (J.P.M.L. 2011)</cite.query>; <cite.query w-src-number="0304914076" w-serial-number="2025867427" w-seq-number="00012" w-ref-type="RP" w-pub-number="0004637" ID="I6c7916276b3e11e99779f698461214a6">In re Jiffy Lube International, Inc., Text Spam Litigation, 802 F. Supp. 2d 1367 (J.P.M.L. 2011)</cite.query>; <cite.query w-src-number="0304914076" w-serial-number="1970100202" w-seq-number="00013" w-ref-type="RP" w-pub-number="0000345" ID="I6c7916296b3e11e99779f698461214a6">In re Ampicillin Antitrust Litigation, 315 F. Supp. 317 (J.P.M.L. 1970)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If5505de06b3e11e99b03e53d6dd36aa2"><label.designator>2</label.designator><footnote.body><para><bop/><bos/><paratext>This factor is discussed as a factor affecting selection of the transferee judge in §§ <cite.query w-ref-type="NA" w-normalized-cite="MDLITMANs7:6" w-pub-number="185218" ID="If5505de16b3e11e99b03e53d6dd36aa2">7:6</cite.query> and  <cite.query w-ref-type="NA" w-normalized-cite="MDLITMANs7:11" w-pub-number="185218" ID="If5505de26b3e11e99b03e53d6dd36aa2">7:11</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If55084f06b3e11e99b03e53d6dd36aa2"><label.designator>3</label.designator><footnote.body><para><bop/><bos/><paratext><cite.query w-src-number="0304914076" w-serial-number="1970100202" w-seq-number="00014" w-ref-type="RP" w-pub-number="0000345" ID="I6c7a75a16b3e11e99779f698461214a6">In re Ampicillin Antitrust Litigation, 315 F. Supp. 317 (J.P.M.L. 1970)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If55084f16b3e11e99b03e53d6dd36aa2"><label.designator>4</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.,</ital> <cite.query w-src-number="0304914076" w-serial-number="2010560083" w-seq-number="00015" w-ref-type="RP" w-pub-number="0004637" ID="I6c7b11e16b3e11e99779f698461214a6">In re Intern. Air Transp. Surcharge Antitrust Litigation, 460 F. Supp. 2d 1377 (J.P.M.L. 2006)</cite.query> (judge experienced in MDL and complex litigation); <cite.query w-src-number="0304914076" w-serial-number="2008553259" w-seq-number="00016" w-ref-type="RP" w-pub-number="0004637" ID="I6c7b11e36b3e11e99779f698461214a6">In re Celexa and Lexapro Products Liability Litigation, 416 F. Supp. 2d 1361 (J.P.M.L. 2006)</cite.query> (experienced MDL judge); <cite.query w-src-number="0304914076" w-serial-number="2008553257" w-seq-number="00017" w-ref-type="RP" w-pub-number="0004637" ID="I6c7b11e56b3e11e99779f698461214a6">In re Vitamin C Antitrust Litigation, 416 F. Supp. 2d 1352 (J.P.M.L. 2006)</cite.query> (judge with MDL experience); <cite.query w-src-number="0304914076" w-serial-number="2008318693" w-seq-number="00018" w-ref-type="RP" w-pub-number="0004637" ID="I6c7b11e76b3e11e99779f698461214a6">In re Viagra Products Liability Litigation, 414 F. Supp. 2d 1357 (J.P.M.L. 2006)</cite.query> (where actions geographically dispersed, transfer to district with judge experienced in MDL actions); <cite.query w-src-number="0304914076" w-serial-number="1975107931" w-seq-number="00019" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1403" ID="I6c7b11e96b3e11e99779f698461214a6">In re Panty Hose Seaming Patent Litigation, 402 F. Supp. 1401, 1403 (J.P.M.L. 1975)</cite.query> (availability of judge apparently primary factor in selecting district); <cite.query w-src-number="0304914076" w-serial-number="1969103260" w-seq-number="00020" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="800" ID="I6c7b11eb6b3e11e99779f698461214a6">In re IBM, 302 F. Supp. 796, 800 (J.P.M.L. 1969)</cite.query>; <cite.query w-src-number="0304914076" w-serial-number="1969103728" w-seq-number="00021" w-ref-type="RP" w-pub-number="0000345" ID="I6c7b11ed6b3e11e99779f698461214a6">In re Koratron, 302 F. Supp. 239 (J.P.M.L. 1969)</cite.query>; <cite.query w-src-number="0304914076" w-serial-number="1969100256" w-seq-number="00022" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1403" ID="I6c7b11ef6b3e11e99779f698461214a6">In re Antibiotic Drugs, 295 F. Supp. 1402, 1403 (J.P.M.L. 1968)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If55084f26b3e11e99b03e53d6dd36aa2"><label.designator>5</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See</ital> <cite.query w-src-number="0304914076" w-serial-number="1977105829" w-seq-number="00023" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1189" ID="I6c7bd5316b3e11e99779f698461214a6">In re Tenneco Inc. Securities Litigation, 426 F. Supp. 1187, 1189 (J.P.M.L. 1977)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote></footnote.block><content.metadata.block><cmd.royalty><cmd.copyright><bop/><bos/>Westlaw. © 2019 Thomson Reuters.  <eos/><bos/>No Claim to Orig. U.S. Govt. <eos/><bos/>Works.<eos/><eop/></cmd.copyright></cmd.royalty><cmd.identifiers><cmd.cites><cmd.first.line.cite><bop/><bos/>MDLITMAN § 6:15<eos/><eop/></cmd.first.line.cite></cmd.cites></cmd.identifiers></content.metadata.block></doc></n-docbody>
